Royal Sense Ltd.
BBSE:ROYAL69.95
INR
-4.05
(-5.47%)
ISIN
INE0QQG01019
Return %
Stock
S&P 500
1Y
-69.59
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Rishabh Arora
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- New Delhi India
- IPO Date
- Mar 19, 2024
- Website
- royalsense.in
- Similar Companies
- Business
- Royal Sense Limited is an India-based healthcare solutions provider engaged in the trading, marketing, and distribution of medical equipment, surgical instruments, pharmaceutical formulations, and diagnostic supplies. The company operates as a comprehensive procurement partner for medical institutions, offering an extensive portfolio categorized into medical devices and surgical instruments, including scalpel blades, forceps, surgical scissors, suction units, and orthopedic implants; surgical consumables and medical disposables, including surgical gloves, face masks, disposable syringes, infusion sets, gauze, bandages, and sterilization wraps, largely marketed under its proprietary brand STERGIC; laboratory equipment and analytical instruments, including centrifuges, microscopes, and spectrophotometers; laboratory reagents, diagnostic test kits, and rapid screening devices; and specialized pharmaceutical products, including antifungal formulations such as IETRACON, therapeutic syrups, oral suspensions, and gastrointestinal binders. Royal Sense supplies its products to state government health departments—including those of Uttar Pradesh, Himachal Pradesh, Rajasthan, and Jammu & Kashmir—as well as municipal healthcare entities, private hospital chains, diagnostic laboratories, and nursing homes across India through a dedicated network of distributors and sub-dealers. Incorporated in April 2023, Royal Sense Limited is headquartered in North West Delhi, India. In March 2024, the company transitioned to a publicly traded entity following its initial public offering (IPO) on the BSE SME platform. In late 2025, the company advanced a corporate consolidation through a proposed scheme of merger by absorption of TTG Innovations Private Limited to expand its operational footprint. The company has continuously broadened its commercial portfolio with strategic pharmaceutical formulation rollouts throughout 2025. In July 2026, the board of directors sanctioned significant expansion and capital structuring plans, including an increase in authorized share capital from INR 10 crore to INR 20 crore, authorization to raise up to INR 500 crore via debt securities, approval for asset acquisitions of up to INR 200 crore, and initiatives to establish branch offices outside India to drive international expansion.